No Data
No Data
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Cuts Target Price to $16
Adverum Biotechnologies Price Target Lowered to $16 From $20 at Mizuho
Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Unlock the Full List